FIELD study

Jump to navigation Jump to search

High Density Lipoprotein Microchapters

Home

Patient information

Overview

Historical Perspective

Classification

Physiology

Pathophysiology

Causes

Low HDL
High HDL

Epidemiology and Demographics

Screening

Natural History, Complications and Prognosis

Diagnosis

HDL Laboratory Test

Treatment

Medical Therapy

Prevention

Future or Investigational Therapies

Clinical Trials

Landmark Trials

List of All Trials

Case Studies

Case #1

FIELD study On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of FIELD study

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on FIELD study

CDC on FIELD study

FIELD study in the news

Blogs on FIELD study

Directions to Hospitals Treating High density lipoprotein

Risk calculators and risk factors for FIELD study

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]

Official Title

Fenofibrate Intervention and Event Lowering in Diabetes

Objective

The objective of this study is to determine the risk of fatal coronary heart disease among subjects with type 2 diabetes who are administered fenofibrate.

Timeline

Timeline
Start Date 01/01/1998
End Date 31/12/2005
Status Completed

Study Description

Study Description
Study Type Randomized
Study Details
Condition Diabetes Mellitus type 2
Intervention Fenofibrate
Placebo
Population Size 9,795

Publications

The administration of fenofibrates among patients with diabetes and either low HDL or hypertension significantly decreased the rate of cardiovascular events. The reduction of cardiovascular events with the administration of fenofibrates was most pronounced among patients with hypertriglyceridemia.[1]

References

  1. Scott R, O'Brien R, Fulcher G, Pardy C, D'Emden M, Tse D; et al. (2009). "Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study". Diabetes Care. 32 (3): 493–8. doi:10.2337/dc08-1543. PMC 2646035. PMID 18984774.